According to a new report Global Pneumonia Vaccines Market, published by KBV research, The Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period.
The North America market dominated the Global Pneumococcal Conjugate Vaccine (PCV) Market by Region in 2018, growing at a CAGR of 2.8 % during the forecast period. The Europe market is expected to witness a CAGR of 3.6% during (2019 - 2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 5.3% during (2019 - 2025).
The Prevnar 13 market dominated the Global Pneumonia Vaccines Market by Product Type in 2018, growing at a CAGR of 4.1 % during the forecast period. The Synflorix market is expected to witness a CAGR of 7.5% during (2019 - 2025). Additionally, The Pneumovax23 market is expected to witness highest CAGR of 8.5% during (2019 - 2025).
The Distribution Partner Companies market dominated the Global Pneumonia Vaccines Market by Distribution Channel in 2018, growing at a CAGR of 4.3 % during the forecast period. The Non-Governmental Organizations (NGO) market is expected to witness a CAGR of 6% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/pneumonia-vaccines-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.
By Vaccine Type
By Product Type
By Sector
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
